Advertisement

Topics

AbbVie's Imbruvica wins FDA nod for chronic graft-vs.-host disease

05:32 EDT 3 Aug 2017 | SmartBrief

AbbVie's Imbruvica, or ibrutinib, has been granted approval by the FDA as a treatment for chronic graft-versus-host disease i -More

Original Article: AbbVie's Imbruvica wins FDA nod for chronic graft-vs.-host disease

NEXT ARTICLE

More From BioPortfolio on "AbbVie's Imbruvica wins FDA nod for chronic graft-vs.-host disease"

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...